Kaleido Biosciences: Rises on positive data from COVID-19 treatment trial
14/01/2021 13:17
** Drug developer's shares KLDO.O up 16.2% at $14.30
premarket; set to touch their highest in more than 1 1/2 years
** Co says its experimental treatment, KB109, along with
self-care practices to treat mild to moderate COVID-19 in
outpatients showed safety and tolerability in a clinical trial
urn:newsml:reuters.com:*:nGNX7p9600
** Median time of recovery in patients was 18 days with co's
treatment, KB109, plus self-care practices, and 27 days with
self-care practices alone - KLDO
** Data from full study population of 350 patients and
results of second study of KB109 are expected in the first
quarter of 2021
** Up to Wednesday's close, stock had more than doubled in
the last 12 months
(Reporting by Dania Nadeem in Bengaluru)
((Dania.Nadeem@thomsonreuters.com;))